Business Context and Reporting Period
This Form 8-K is a current report filed by RXi Pharmaceuticals Corporation (also referenced as Phio Pharmaceuticals Corp. in metadata) for the event date of August 31, 2018. The filing addresses a specific compensatory arrangement for the Company's Chief Executive Officer, Geert Cauwenbergh, Dr. Med. Sc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation terms rather than financial performance metrics.
Material Changes
The material change reported is the Board of Directors' approval of a non-plan stock compensation election for the CEO. Effective September 15, 2018, through December 31, 2018, the CEO may elect to receive up to 50% of his base salary and cash bonuses in the form of unvested, restricted shares of common stock instead of cash.
Guidance, Outlook, and Management Commentary
- Compensation Structure: The restricted shares will be granted on each payroll date during the specified period.
- Vesting Schedule: Shares will vest in full on January 1, 2019, contingent upon the CEO's continued employment through that date.
- Plan Status: These grants are issued outside of the Company's 2012 Long Term Incentive Plan and Employee Stock Purchase Plan.
- Documentation: Full terms are detailed in the "Non-Plan Stock Compensation Election and Terms and Conditions" filed as Exhibit 10.1.
Investor Verification Checklist
- Verify the exact number of restricted shares issued to the CEO during the September to December 2018 period.
- Confirm the CEO's continued employment status as of January 1, 2019, to ensure vesting conditions were met.
- Review Exhibit 10.1 for specific valuation methods used for the stock grants and any tax implications.
- Check subsequent filings to determine if this compensation structure was extended beyond the initial four-month period.